Lymph Node Metastases and Associated Recurrence-Free Survival in Microsatellite Stable and Unstable Colon Cancer.

Autor: Hakki, Lynn, Khan, Asama, Gonen, Mithat, Stadler, Zsofia, Segal, Neil H., Shia, Jinru, Widmar, Maria, Wei, Iris H., Smith, J. Joshua, Pappou, Emmanouil P., Nash, Garrett M., Paty, Philip B., Garcia-Aguilar, Julio, Weiser, Martin R.
Zdroj: Annals of Surgical Oncology: An Oncology Journal for Surgeons; Dec2023, Vol. 30 Issue 13, p8487-8494, 8p
Abstrakt: Background: In contrast to microsatellite stable (MSS) colon cancer, predictors of lymph node metastases and their association with recurrence are not well-defined in microsatellite instability (MSI) colon cancer. Methods: A cohort of nonmetastatic colon cancer patients undergoing surgery between 2015 and 2021 were evaluated for predictors of lymph node metastases (LNMs) and their association with recurrence-free survival (RFS). Results: Of 1466 patients included in the analyses, 361 (25 %) had MSI. Compared with MSS, MSI was associated with earlier stage, fewer LNMs in the patients with N1 or N2 disease, and fewer high-risk features. Compared with the T3–T4 MSS patients, the odds ratios for LNM were 0.52 (95% confidence interval [CI], 0.38–0.71) for the T3–T4 MSI patients, 0.27 (95% CI, 0.38–0.71) for the T1–T2 MSS patients, and 0.15 (95 % CI, 0.08–0.26) for the T1–T2 MSI patients. In both groups, LNMs were associated with T category, patient age, and venous, lymphatic, or perineural invasion. In the MSS patients, LNMs were additionally associated with patient sex and histologic grade. Compared with the MSS patients, the MSI patients with N0 and N1 disease had a better 3-year RFS. However, the MSI patients with N2 disease had a lower rate of 3-year RFS than the MSS patients (hazard ratio, 19.75 vs 4.49). Conclusions: In MSI colon cancer, LNMs are 50 % less prevalent, but the factors associated with LNM are like those in MSS colon cancer. The improved prognosis traditionally associated with early-stage MSI colon cancers dissipates with four or more LNMs. These findings should be taken into consideration by clinicians selecting the most appropriate course of treatment for MSI colon cancer. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: